Patent · US Active

2′,4′-fluoro nucleosides for the treatment of HCV

US9187515B2 · kind B2 · utility

40Cited by

138References

16Claims

0Family size

Assignee

Idenix Pharmaceuticals LLC · US

Inventors

Benjamin Alexander Mayes · Boston, US
Adel Moussa · Burlington, US
Alistair James Stewart · Lincoln, US

Key dates

Filing date	Apr 1, 2014
Grant date	Nov 17, 2015
Priority date	—
Expiry date	Apr 1, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07H19/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2′,4′-fluoro nucleosides according to Formula 1001:or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2′,4′-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.